In these glioma cells, suitable ionic gradients need to be established through the activity of ion transport systems, such as NKCC1. While a loss of NKCC1 function does not compromise cell motility in two-dimensional assays that lack spatial constraints, it manifests when cells have to undergo volume changes during locomotion. This evidence concerns the gene SLC12A2 and central nervous system cancer.